OptiNose

OptiNose — Q1 2023 Earnings Presentation

19 slides from OptiNose's earnings presentation, May 11, 2023

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 1 , 2 0 2 3 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this

  3. Slide 3: Key Takeaways

    3 Key Takeaways Chronic sinusitis is a 10‐fold market opportunity for XHANCE Executing our strategy to prioritize the potential launch of XHANCE as the first‐ever FDA approved drug treatment for CS sNDA accepted for review by FDA – Target action date in December 2023

  4. Slide 4: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis: New Growth Opportunities

    4 Successful Development of XHANCE as the First and Only FDA‐approved Drug Treatment for Chronic Sinusitis Would Create Multiple New Growth Opportunities Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Mil

  5. Slide 5: ReOpen Program Update

    ReOpen Program Update

  6. Slide 6: CS Supplemental NDA - Anticipated Next Steps

    6 CS Supplemental NDA ‐ Anticipated Next Steps  FDA accepted for review our supplemental new drug application (sNDA) in pursuit of a new indication  PDUFA target action date is in December 2023 - Standard review period was applied

  7. Slide 7: Q1 2023 Performance

    Q1 2023 Performance

  8. Slide 8: XHANCE Prescriptions

    8 XHANCE Prescriptions XHANCE New Prescriptions increased 3% and Total Prescriptions increased 1% and HCPs who had more than 15 prescriptions filled by their patients decreased 1% from Q1 2022 to Q1 2023 29.5 30.4 Q1 '22 Q1 '23 (in thousands) XHANCE New Prescriptions 83.5 84.4 Q1 '22 Q1 '23 XHANCE T

  9. Slide 9: Q1 2023 Financial Update

    Q1 2023 Financial Update

  10. Slide 10: Financial Review – First Quarter 2023

    10 Financial Review – First Quarter 2023 SG&A plus R&D expenses decreased by ~$10M from Q1 2022 to Q1 2023 while Q1 2023 XHANCE Net Revenues exceeded previous guidance of approximately $10 million $34.1 $24.5 Q1 '22 Q1 '23 ($M) SG&A plus R&D Expenses $14.8 $11.8 Q1 '22 Q1 '23 ($M) Net Revenue Averag

  11. Slide 11: 2023 Outlook

    optinose_ ———— 2023 Outlook

  12. Slide 12: Full Year 2023 Financial Guidance

    12 Full Year 2023 Financial Guidance  GAAP Operating Expenses (SG&A and R&D Expenses) ‒ Expected to be between $88 to $93 million; approximately $6 million of which represents stock‐based compensation ‒ Previously expected to be between $90 to $95 million; approximately $8 million of which represen

  13. Slide 13: Closing Remarks

    optinose_ ———— Closing Remarks

  14. Slide 14: Key Takeaways

    14 Key Takeaways Chronic sinusitis is a 10‐fold market opportunity for XHANCE Executing our strategy to prioritize the potential launch of XHANCE as the first‐ever FDA approved drug treatment for CS sNDA accepted for review by FDA – Target action date in December 2023

  15. Slide 15: Investor Relations – Optinose Investor Contact

    15 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267‐521‐0531 Investors@optinose.com As of March 31, 2023: – $83.9 million in cash – Debt: $130 million – 112 million common shares o/s – 46 million options, warrants & RSUs

  16. Slide 16: Appendix - ReOpen Program Co-Primary Endpoints

    Appendix ‐ ReOpen Program Co‐Primary Endpoints

  17. Slide 17: Combined Symptom Score (Co-Primary Endpoint)

    17 Combined Symptom Score (Co‐Primary Endpoint) Improvement in combined symptoms with XHANCE; Consistent with NAVIGATE I and II 1 ‐0.81 ‐1.54* ‐1.74‡ ‐2.0 ‐1.8 ‐1.6 ‐1.4 ‐1.2 ‐1.0 ‐0.8 ‐0.6 ‐0.4 ‐0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS‐placebo BID OPN‐375

  18. Slide 18: Average of Percentages of Opacified Volume (Ethmoid and Maxillary)

    18 Average of Percentages of Opacified Volume (Ethmoid and Maxillary) Objective Evidence of Effect in Sinus Cavities by CT Scan; Co‐Primary Endpoint 1.19 ‐7.00‡ ‐5.14♰ ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 2 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to

  19. Slide 19: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 1 , 2 0 2 3

OptiNose — Q1 2023 Earnings Presentation on 6ix